(Q36378036)

13 August 2017

1 reference

title

Pyrimidine and purine analogues, effects on cell cycle regulation and the role of cell cycle inhibitors to enhance their cytotoxicity (English)

1 reference

13 August 2017

0 references

Jennifer Sigmond

1

1 reference

13 August 2017

Godfridus J Peters

series ordinal

2

1 reference

13 August 2017

publication date

1 January 2005

1 reference

Nucleosides, Nucleotides & Nucleic Acids

13 August 2017

published in

1 reference

13 August 2017

volume

24

1 reference

13 August 2017

issue

10-12

1 reference

13 August 2017

page(s)

1997-2022

1 reference

The cdk-activating kinase (CAK): from yeast to mammals.

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F15257770500269556

Requirement for tyrosine phosphorylation of Cdk4 in Gl arrest induced by ultraviolet irradiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15257770500269556

Mechanisms of action of flavopiridol

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15257770500269556

The protein kinases of Caenorhabditis elegans: a model for signal transduction in multicellular organisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15257770500269556

The protein tyrosine kinase family of the human genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15257770500269556

Proteasome-dependent regulation of p21WAF1/CIP1 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15257770500269556

Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15257770500269556

Inhibition of cyclin D1 phosphorylation on threonine-286 prevents its rapid degradation via the ubiquitin-proteasome pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15257770500269556

Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15257770500269556

Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15257770500269556

The histone-deacetylase inhibitor Trichostatin A blocks proliferation and triggers apoptotic programs in hepatoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15257770500269556

Histone deacetylase inhibitors--a new tool to treat cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15257770500269556

Chemical inhibitors of cyclin-dependent kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15257770500269556

Staurosporine promotes endothelial cell assembly and FAK phosphorylation during in vitro angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15257770500269556

UCN-01, 7-hydroxyl-staurosporine, inhibits kinase activity of cyclin-dependent kinases and reduces the phosphorylation of the retinoblastoma susceptibility gene product in A549 human lung cancer cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15257770500269556

Interference with PDK1-Akt survival signaling pathway by UCN-01 (7-hydroxystaurosporine).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15257770500269556

The specificities of protein kinase inhibitors: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15257770500269556

Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15257770500269556

The Cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) inhibits retinoblastoma protein phosphorylation, causes loss of Cyclin D1, and activates the mitogen-activated protein kinase pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15257770500269556

Roscovitine-induced up-regulation of p53AIP1 protein precedes the onset of apoptosis in human MCF-7 breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15257770500269556

A novel CDK inhibitor, CYC202 (R-roscovitine), overcomes the defect in p53-dependent apoptosis in B-CLL by down-regulation of genes involved in transcription regulation and survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15257770500269556

Activation of p53 by roscovitine-mediated suppression of MDM2 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15257770500269556

Cyclin-dependent kinase inhibitor Roscovitine induces apoptosis in chronic lymphocytic leukemia cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15257770500269556

Cyclin-dependent kinase inhibitors block proliferation of human gastric cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15257770500269556

The cyclin-dependent kinase inhibitors olomoucine and roscovitine arrest human fibroblasts in G1 phase by specific inhibition of CDK2 kinase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15257770500269556

Abrogation of the S phase DNA damage checkpoint results in S phase progression or premature mitosis depending on the concentration of 7-hydroxystaurosporine and the kinetics of Cdc25C activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15257770500269556

A unified view of the DNA-damage checkpoint

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15257770500269556

The DNA damage response: putting checkpoints in perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15257770500269556

Cell-cycle checkpoint kinases: checking in on the cell cycle

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15257770500269556

Linkage of ATM to cell cycle regulation by the Chk2 protein kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15257770500269556

A human homologue of the checkpoint kinase Cds1 directly inhibits Cdc25 phosphatase

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15257770500269556

HOX11 interacts with protein phosphatases PP2A and PP1 and disrupts a G2/M cell-cycle checkpoint

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15257770500269556

Cell cycle control and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15257770500269556

Beyond the Nobel Prize: cell cycle research offers new view of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15257770500269556

Design of new anticancer therapies targeting cell cycle checkpoint pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15257770500269556

Anticancer drug targets: cell cycle and checkpoint control.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15257770500269556

Mechanisms of cell-cycle checkpoints: at the crossroads of carcinogenesis and drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15257770500269556

Determinants of trifluorothymidine sensitivity and metabolism in colon and lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15257770500269556

Cladribine (2-chlorodeoxyadenosine)

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15257770500269556

Fludarabine. A review of its pharmacological properties and therapeutic potential in malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15257770500269556

Fludarabine inhibits DNA replication: a rationale for its use in the treatment of acute leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15257770500269556

Oral antilymphocyte activity and induction of apoptosis by 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15257770500269556

Clofarabine in adult acute leukemias: clinical success and pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15257770500269556

Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15257770500269556

Preclinical antitumor activity of 2-chloro-9-(2-deoxy-2-fluoro-beta-D- arabinofuranosyl)adenine (Cl-F-ara-A).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15257770500269556

Cloning of a human nucleoside transporter implicated in the cellular uptake of adenosine and chemotherapeutic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15257770500269556

Comparison of the interaction of uridine, cytidine, and other pyrimidine nucleoside analogues with recombinant human equilibrative nucleoside transporter 2 (hENT2) produced in Saccharomyces cerevisiae

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15257770500269556

Gemcitabine transport in xenopus oocytes expressing recombinant plasma membrane mammalian nucleoside transporters.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15257770500269556

Differential transport of cytosine-containing nucleosides by recombinant human concentrative nucleoside transporter protein hCNT1

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15257770500269556

Electrogenic uptake of nucleosides and nucleoside-derived drugs by the human nucleoside transporter 1 (hCNT1) expressed in Xenopus laevis oocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15257770500269556

Determinants of sensitivity and resistance to gemcitabine: the roles of human equilibrative nucleoside transporter 1 and deoxycytidine kinase in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15257770500269556

The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15257770500269556

Comparative study of a novel nucleoside analogue (Troxatyl, troxacitabine, BCH-4556) and AraC against leukemic human tumor xenografts expressing high or low cytidine deaminase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15257770500269556

Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with refractory leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15257770500269556

Troxacitabine, an L-stereoisomeric nucleoside analog, on a five-times-daily schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15257770500269556

Phase II study of troxacitabine (BCH-4556) in patients with advanced and/or metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada-Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15257770500269556

Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15257770500269556

Augmentation of 1-beta-D-arabinofuranosylcytosine (Ara-C) cytotoxicity in leukaemia cells by co-administration with antisignalling drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15257770500269556

UCN-01 (7-hydroxystaurosporine) enhances 5-fluorouracil cytotoxicity through down-regulation of thymidylate synthetase messenger RNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15257770500269556

Combinations of 5-fluorouracil with UCN-01 or staurosporine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15257770500269556

Inhibition of cyclin-dependent kinase 2 by the Chk1-Cdc25A pathway during the S-phase checkpoint activated by fludarabine: dysregulation by 7-hydroxystaurosporine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15257770500269556

UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15257770500269556

EGF-mediated phosphorylation of extracellular signal-regulated kinases in osteoblastic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15257770500269556

Inhibitors of protein kinases: CGP 41251, a protein kinase inhibitor with potential as an anticancer agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15257770500269556

Negative regulation of the growth-promoting transcription factor E2F-1 by a stably bound cyclin A-dependent protein kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15257770500269556

Cyclin A-kinase regulation of E2F-1 DNA binding function underlies suppression of an S phase checkpoint

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15257770500269556

Differential regulation of E2F transactivation by cyclin/cdk2 complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15257770500269556

Cyclin A/CDK2 binds directly to E2F-1 and inhibits the DNA-binding activity of E2F-1/DP-1 by phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15257770500269556

Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15257770500269556

Advances in chemotherapy for chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15257770500269556

Review of UCN-01 development: a lesson in the importance of clinical pharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15257770500269556

Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxystaurosporine in combination with Fluorouracil in patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15257770500269556

A phase I trial of daily oral 4'- N -benzoyl-staurosporine in combination with protracted continuous infusion 5-fluorouracil in patients with advanced solid malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15257770500269556

Phase I study of PKC412 (N-benzoyl-staurosporine), a novel oral protein kinase C inhibitor, combined with gemcitabine and cisplatin in patients with non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15257770500269556

Phase II study of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C alpha, in patients with previously treated low-grade non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15257770500269556

In vitro and in vivo pharmacokinetic-pharmacodynamic relationships for the trisubstituted aminopurine cyclin-dependent kinase inhibitors olomoucine, bohemine and CYC202.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15257770500269556

UCN-01, a protein kinase C inhibitor, inhibits endothelial cell proliferation and angiogenic hypoxic response

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15257770500269556

Polo-like kinase-1 is a target of the DNA damage checkpoint

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15257770500269556

UCN-01 and UCN-02, new selective inhibitors of protein kinase C. II. Purification, physico-chemical properties, structural determination and biological activities

21 January 2018

1 reference

12 April 2024

https://opencitations.net/index/api/v1/citations/10.7164/ANTIBIOTICS.42.571

Identifiers

DOI

10.1080/15257770500269556

1 reference

release_qmhxoesswjbe3cdicnaodj7ilm

13 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/qmhxoesswjbe3cdicnaodj7ilm

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference